Richard G. Harris, MD

Richard G. Harris, MD

UroPartners

Chicago, Illinois

Richard Harris, MD, is a board-certified urologist with expertise in the treatment of advanced prostate cancer and health policy. He obtained his BA cum laude from Washington University in St. Louis, Missouri. He then completed a year of graduate work in biological science at the University of Illinois in Chicago, followed by medical school at the Chicago Medical School at Rosalind Franklin University. He completed residency training in general surgery and urology at Loyola University Medical Center in Chicago. Dr. Harris has been involved in clinical drug development and research on over 70 drug trials and has also been on the advisory board for several pharmaceutical companies. Currently, he sits on the Board of Directors of LUGPA and is LUGPA’s President. He is a founding member, CEO, and President of UroPartners, LLC, the largest group of urologists in the Midwest.

Dr. Harris is an Assistant Clinical Professor of Urology at the Loyola University Medical Center. His area of interest is urology and his specialty is advanced prostate cancer. Dr. Harris is also interested in BPH, sexual dysfunction, and kidney stone disease. Dr. Harris is one of the few urologists skilled in cryotherapy for prostate cancer.

Disclosures:

Talks by Richard G. Harris, MD

Panel Discussion on Challenges of Managing Androgen Deprivation Therapy Patients During COVID-19

Panel Discussion on Challenges of Managing Androgen Deprivation Therapy Patients During COVID-19

Posted by | Jul 2020

Richard Harris, MD, President of LUGPA and UroPartners, moderates a discussion between Daniel R. Saltzstein, MD, from Urology San Antonio, and Timothy D. Langford, MD, from Arkansas Urology. They discuss the challenges of managing prostate cancer patients during COVID-19, including the ways the pandemic has changed the manner and frequency of how they bring in patients in for treatment, particularly for therapies like androgen deprivation. Both Dr. Saltzstein and Dr. Langford emphasize the precautions they are taking at their practices to address the risks of COVID-19, and acknowledge how challenging this patient population can be given their need for frequent visits. They highlight the limitations of telehealth, as well as the risks of not bringing patients in often enough to receive the therapies that they need, even though lengthening the time between visits has been the answer a lot of doctors have found to reduce the risk of COVID-19 exposure.

Read More
Managing Prostate Cancer Patients and LHRH Injection Times During COVID-19

Managing Prostate Cancer Patients and LHRH Injection Times During COVID-19

Posted by | Jun 2020

Richard Harris, MD, President of LUGPA and UroPartners, moderates a discussion between Daniel R. Saltzstein, MD, from Urology San Antonio, and Timothy D. Langford, MD, from Arkansas Urology. They discuss the challenges of managing prostate cancer patients during COVID-19, including the ways the pandemic has changed the manner and frequency of how they bring in patients in for treatment, particularly for therapies like androgen deprivation. Both Dr. Saltzstein and Dr. Langford emphasize the precautions they are taking at their practices to address the risks of COVID-19, and acknowledge how challenging this patient population can be given their need for frequent visits. They highlight the limitations of telehealth, as well as the risks of not bringing patients in often enough to receive the therapies that they need, even though lengthening the time between visits has been the answer a lot of doctors have found to reduce the risk of COVID-19 exposure.

Read More
The Present and Future of LUGPA

The Present and Future of LUGPA

Posted by | May 2020

Richard G. Harris, MD, discusses the Large Urology Group Practice Association’s (LUGPA) 2020 Strategic Plan. He observes that as the United States’ population ages and grows, and as new technology causes the cost of treatment to rise, demands on urology practices will increase. LUGPA will help urologists meet these challenges by continuing its advocacy work protecting independent urology practice, especially in Washington, D.C., and by developing the leadership skills of young urologists through programs like LUGPA Forward and the Rising Chief Resident Summit. Other initiatives will focus on easing operational challenges, increasing member engagement, and ensuring organizational excellence.

Read More
Advanced Prostate Cancer: What’s Changing

Advanced Prostate Cancer: What’s Changing

Posted by | Apr 2020

Richard G. Harris, MD, President of LUGPA and UroPartners, discusses the recent incorporation of advanced prostate cancer (APC) clinics amongst LUGPAs within the United States. He goes on to discuss why APC clinics are important, clinical trials for m0, m1, and castrate sensitive prostate cancer, as well as the importance of genetic testing within an APC clinic.

Read More
The Effect of COVID-19 on Large Urology Groups: The LUGPA Perspective

The Effect of COVID-19 on Large Urology Groups: The LUGPA Perspective

Posted by | Apr 2020

Richard G. Harris, MD, President of LUGPA and UroPartners, discusses the changes being implemented at LUGPAs as a result of the COVID-19 pandemic. He notes how surgery and radiation centers are only treating patients with strong suspicion of high-risk disease, and how patients undergoing current radiation treatment protocols are maintaining continuation of care, with added safety protocols built in. These safety protocols include: hypervigilance for patient and staff safety, including mandatory masks and gloves for all staff; mandatory temperature readings before patients are allowed in the clinic; and evaluating patients prior to clinic admission for possible symptoms of COVID-19. Lastly, Dr. Harris discusses the use of telemedicine in the clinic, and how he hopes regulations that make it easier to see patients remotely will stay in place once the pandemic is behind us.

Read More

Join the GRU Community

- Why Join? -